Form 4: Bio-Techne Exec Boosts Equity Holdings

Sentiment:

Insider Trading Report 19 August 2025 5:28 PM

A Bio-Techne Corp. executive reported significant equity transactions, including the acquisition of new stock options and restricted stock units, alongside the exercise of existing awards.

Summary

Shane Bohnen, SVP General Counsel of Bio-Techne Corp. (TECH), reported equity transactions on August 15, 2025.
Acquired 1,718 shares of common stock through the exercise or conversion of derivative securities at a price of $0.
Disposed of 527 shares of common stock at $53.6 per share to cover tax liabilities.
Beneficial ownership of common stock after these transactions is 4,385 shares.
Acquired new equity awards: 13,992 Performance Restricted Stock Units, 6,996 Restricted Stock Units, and 17,897 Stock Options with an exercise price of $53.6 and an expiration date of August 15, 2035.
Various existing stock options and restricted stock units are detailed, with vesting schedules extending to 2028 and expiration dates up to 2035.

Sentiment

Score: 7

Explanation: The filing indicates routine executive equity transactions, including the grant of new long-term incentives and the exercise/vesting of existing awards. The disposition of shares for tax purposes is a neutral event. Overall, it reflects ongoing executive compensation and alignment with shareholder interests, which is generally positive for corporate governance and stability.

Positives

Acquisition of 13,992 Performance Restricted Stock Units, aligning executive incentives with company performance.
Acquisition of 6,996 Restricted Stock Units, providing future equity ownership.
Grant of 17,897 new Stock Options with an exercise price of $53.6, indicating long-term incentive.
Exercise of 1,718 shares from derivative securities, increasing direct shareholding.

Negatives

Disposition of 527 shares at $53.6 per share to satisfy tax withholding obligations, which reduces direct share ownership.

Risks

Performance-based equity awards (PRSUs) are contingent on achieving specific company performance goals, meaning the full award may not vest.
Stock options' value is dependent on the future market price of Bio-Techne common stock exceeding their respective exercise prices.
Vesting schedules for various equity awards extend several years into the future, tying a significant portion of compensation to long-term company performance and continued employment.

Future Outlook

The filing details future vesting schedules for various equity awards, including stock options and restricted stock units, extending through August 2028, and performance-based awards contingent on achieving specific goals by August 2028. New stock options granted have an expiration date of August 15, 2035, indicating a long-term incentive horizon.

Management Comments

Not applicable. Form 4 filings do not typically contain management commentary or quotes, as they are transactional reports.

Industry Context

This Form 4 filing reflects standard executive compensation practices within the biotechnology and life sciences tools industry, where equity-based incentives like stock options and restricted stock units are commonly used to align management interests with long-term shareholder value creation. The grant of new equity awards is a routine part of annual compensation cycles, while the exercise of options and vesting of RSUs, often accompanied by tax-related dispositions, are typical events for executives managing their equity portfolios.

Comparison to Industry Standards

The equity compensation structure, involving a mix of stock options, restricted stock units, and performance-based restricted stock units, is consistent with common practices among publicly traded companies in the life sciences sector, such as Thermo Fisher Scientific (TMO), Danaher Corporation (DHR), and Agilent Technologies (A).
The vesting schedules, typically over 3-5 years, and performance conditions for PRSUs, are standard mechanisms to promote long-term retention and performance alignment.
The disposition of shares for tax withholding is a routine and expected event when equity awards vest or options are exercised, aligning with tax regulations for non-cash compensation.

Stakeholder Impact

Shareholders: The grant of new equity awards aligns executive incentives with shareholder value creation. The exercise and vesting of awards demonstrate management's direct stake in the company.
Employees: While specific to one executive, these transactions reflect the company's broader equity compensation strategy, which can impact employee retention and motivation.

Next Steps

Future vesting of various stock options and restricted stock units on specified dates through August 2028.
Achievement of performance goals for Performance Restricted Stock Units by August 2026, August 2027, and August 2028 for full or partial vesting.
Potential future exercises of newly granted stock options with an expiration date of August 15, 2035.

Key Dates

Date	Description
08/15/2023	Vesting date for 876 shares of stock option with $94.52 exercise price.
04/03/2024	Vesting date for 982 shares of stock option with $73.76 exercise price.
08/15/2024	Vesting date for 880 shares of stock option with $94.52 exercise price; Vesting date for 4,076 shares of stock option with $84.61 exercise price.
04/03/2025	Vesting date for 982 shares of stock option with $73.76 exercise price.
08/15/2025	Transaction date for all reported changes; Vesting date for 876 shares of stock option with $94.52 exercise price; Vesting date for 4,075 shares of stock option with $84.61 exercise price; Vesting date for 3,372 shares of stock option with $74.91 exercise price.
04/03/2026	Vesting date for 982 shares of stock option with $73.76 exercise price.
08/07/2026	Expiration date for stock option with $47.6 exercise price.
08/15/2026	Vesting date for 876 shares of stock option with $94.52 exercise price; Vesting date for 4,076 shares of stock option with $84.61 exercise price; Vesting date for 2,259 restricted stock units; Vesting date for 49 restricted stock units; Vesting date for 1,669 restricted stock units; Vesting date for 3,372 shares of stock option with $74.91 exercise price; Vesting date for 2,332 restricted stock units; Vesting date for 5,966 shares of stock option with $53.6 exercise price.
04/03/2027	Vesting date for 982 shares of stock option with $73.76 exercise price.
08/05/2027	Expiration date for stock option with $66.97 exercise price.
08/15/2027	Vesting date for 4,075 shares of stock option with $84.61 exercise price; Vesting date for 1,669 restricted stock units; Vesting date for 3,372 shares of stock option with $74.91 exercise price; Vesting date for 2,332 restricted stock units; Vesting date for 5,966 shares of stock option with $53.6 exercise price.
08/06/2028	Expiration date for stock option with $120.46 exercise price.
08/15/2028	Vesting date for 3,372 shares of stock option with $74.91 exercise price; Vesting date for 2,332 restricted stock units; Vesting date for 5,965 shares of stock option with $53.6 exercise price.
08/15/2029	Expiration date for stock option with $94.52 exercise price.
04/03/2030	Expiration date for stock option with $73.76 exercise price.
08/15/2030	Expiration date for stock option with $84.61 exercise price.
08/15/2034	Expiration date for stock option with $74.91 exercise price.
08/15/2035	Expiration date for stock option with $53.6 exercise price.
08/19/2025	Signature date of reporting person.

Recommendation

hold

This Form 4 filing details routine insider equity transactions for an executive. It shows the executive receiving new equity awards and exercising/vesting existing ones, which is a standard part of executive compensation and aligns management interests with shareholders. There are no new material financial results, strategic shifts, or significant risks disclosed that would warrant a change in investment recommendation based solely on this filing. It's a neutral event for stock price movement.

Keywords

Bio-Techne, TECH, SEC Form 4, Insider Trading, Equity Compensation, Stock Options, Restricted Stock Units, Performance Shares, Executive Compensation, Corporate Governance

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.